EXTON, Pa.--(BUSINESS WIRE)--Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced today that the company has received notice of $1.6M in additional funding from the U.S. Department of Defense to support the continuing development of biologic-based monoclonal antibody (mAb) therapies against staphylococcal-derived toxins. In June 2008, Morphotek received $1.7M of funding to support the initial development of this project.
